Lung cancer is the leading cause of cancer related deaths all around the world. Although there are various advanced treatment options and several approaches, the survival rate remains low. Here, in this article, we provide an overview of the efficacy of Tumor-infiltrating therapy for lung cancer. Let’s find out how the TIL therapy works.
Tumor-infiltrating lymphocyte (TIL) therapy is a personalized form of cancer treatment and has demonstrated remarkable potential in recent studies. TIL therapy involves extracting TILs from a patient’s tumor and then expanding them in the lab and then reinfusing them into the patient. This is often done after lymphodepleting chemotherapy followed by high-dose interlukin-2. The first step is to obtain necessary tumor tissues via surgical removal and it is usually taken from a metastasis. The TILs are multiplied in the laboratory and the patients then receive a brief chemotherapy pretreatment so that the large number of immune cells can be administered. The immune cells are returned to the patient via infusion and this process is to be done only once.
Lung cancer patients can be suitable for TIL therapy due to its high mutational burden. Also, it has shown promising results for non-small cell lung cancer to immune checkpoint inhibitors. Few clinical trials have shown favorable results of TIL therapy in patients with lung cancer. TIL therapy for lung cancer is only offered as an experimental treatment and is currently available to patients with advanced/metastatic melanoma or non-small cell lung carcinoma.
TIL therapy is currently available at only a few specialized centres worldwide and typically through clinical trials or early access programmes.
The information shared in this blog is for educational purposes only. You should always consult with your medical practitioner for any health advice.
Subscribe to our newsletter or follow us on Facebook or Twitter today and never miss out an update!